ASCO Abstract Preview: ImClone, Genentech

I spent a couple of days culling through the thousands of ASCO abstract titles, looking for those that seemed the most significant to biotech and drug investors. However, this doesn't necessarily mean that there will be a lot of market-moving data, if any, in the actual abstracts when they're posted online May 15.

Sometimes, abstracts can be chock-full of clinical data that don't change much once the meeting gets under way and the final data are presented. In other instances, the abstracts are more placeholders, with little relevant information.

Therefore, I hope you'll use this list more as a guide to what might be potentially important information coming out of the ASCO meeting. And if shares of a certain cancer-related biotech stock move wildly up or down on May 16, you'll be able to check it against this list to see if the volatility is ASCO-related.

Without further delay, here is my list of notable ASCO research abstracts, in alphabetical order by company name.

---

Amgen AMGN:

Abstract No. 2051: Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme.

---

Ariad Pharmaceuticals ARIA:

Abstract No. 3509: Deforolimus trial 106-A phase I trial evaluating seven regimens of oral Deforolimus (AP23573, MK-8669).

---

Arqule ARQL:

Abstract No. 3584: Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral, twice-a-day schedule.